Adriana M MontaÃ±o

List of Publications by Year
in descending order

59 papers	2,276 citations	172457 29 h-index	214800 47 g-index
69 all docs	69 docs citations	69 times ranked	1551 citing authors

#	Article	IF	Citations
1	Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Human Mutation, 2005, 26, 500-512.	2.5	140
2	Clinical course of sly syndrome (mucopolysaccharidosis type VII). Journal of Medical Genetics, 2016, 53, 403-418.	3.2	133
3	Newborn screening and diagnosis of mucopolysaccharidoses. Molecular Genetics and Metabolism, 2013, 110, 42-53.	1.1	131
4	Growth charts for patients affected with Morquio A disease. American Journal of Medical Genetics, Part A, 2008, 146A, 1286-1295.	1.2	122
5	Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Analytical Biochemistry, 2007, 368, 79-86.	2.4	109
6	Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome). Human Mutation, 2009, 30, 511-519.	2.5	99
7	Enzyme replacement therapy in a murine model of Morquio A syndrome. Human Molecular Genetics, 2007, 17, 815-824.	2.9	89
8	Therapies for the bone in mucopolysaccharidoses. Molecular Genetics and Metabolism, 2015, 114, 94-109.	1.1	81
9	Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II. Biology of Blood and Marrow Transplantation, 2017, 23, 1795-1803.	2.0	80
10	Enhancement of Drug Delivery: Enzyme-replacement Therapy for Murine Morquio A Syndrome. Molecular Therapy, 2010, 18, 1094-1102.	8.2	77
11	Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry. Molecular Genetics and Metabolism, 2010, 99, 124-131.	1.1	63
12	Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome. Drug Design, Development and Therapy, 2015, 9, 1937.	4.3	62
13	Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry. Journal of Inherited Metabolic Disease, 2017, 40, 151-158.	3.6	61
14	Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I. Journal of Inherited Metabolic Disease, 2010, 33, 141-150.	3.6	59
15	Assessment of bone dysplasia by microâ€CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. Journal of Inherited Metabolic Disease, 2013, 36, 235-246.	3.6	56
16	Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatographyâ€“tandem mass spectrometry. Journal of Inherited Metabolic Disease, 2010, 33, 35-42.	3.6	55
17	Establishment of Glycosaminoglycan Assays for Mucopolysaccharidoses. Metabolites, 2014, 4, 655-679.	2.9	55
18	Mucopolysaccharidosis IVA: Correlation between genotype, phenotype and keratan sulfate levels. Molecular Genetics and Metabolism, 2013, 110, 129-138.	1.1	54

#	Article	IF	Citations
19	Development of MPS IVA mouse (Galnstm(hC79SÂ·mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase. Human Molecular Genetics, 2005, 14, 3321-3335.	2.9	52
20	Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Research and Reports in Endocrine Disorders, 2012, 2012, 65.	0.4	51
21	Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. Molecular Genetics and Metabolism, 2008, 94, 178-189.	1.1	44
22	Activities of daily living in patients with Hunter syndrome: Impact of enzyme replacement therapy and hematopoietic stem cell transplantation. Molecular Genetics and Metabolism, 2015, 114, 161-169.	1.1	42
23	Comparison of Liquid Chromatographyâ€“Tandem Mass Spectrometry and Sandwich ELISA for Determination of Keratan Sulfate in Plasma and Urine. Biomarker Insights, 2011, 6, BMI.S7451.	2.5	38
24	Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase. Molecular Genetics and Metabolism, 2007, 91, 69-78.	1.1	37
25	Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB. JIMD Reports, 2014, 21, 1-13.	1.5	36
26	Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet Journal of Rare Diseases, 2021, 16, 241.	2.7	33
27	Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model. Molecular Genetics and Metabolism, 2012, 107, 161-172.	1.1	32
28	Murine model (Galnstm(C76S)slu) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins. Molecular Genetics and Metabolism, 2007, 91, 251-258.	1.1	31
29	Adenoâ€associated virus gene transfer in Morquioâ€ƒA diseaseâ€ƒâ€“â€ƒeffect of promoters and sulfataseâ€modifying factorâ€ƒ1. FEBS Journal, 2010, 277, 3608-3619.	4.7	31
30	Sacral dimple: incidental findings from newborn evaluation (Case Presentation). Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 768-769.	1.5	30
31	Identification of a Novel Chondroitin Hydrolase in Caenorhabditis elegans. Journal of Biological Chemistry, 2008, 283, 14971-14979.	3.4	29
32	Evolutionary origin of peptidoglycan recognition proteins in vertebrate innate immune system. BMC Evolutionary Biology, 2011, 11, 79.	3.2	29
33	Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. Journal of Analytical & Bioanalytical Techniques, 2014, s2, 006.	0.6	29
34	Therapies of mucopolysaccharidosis IVA (Morquio A syndrome). Expert Opinion on Orphan Drugs, 2013, 1, 805-818.	0.8	28
35	Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: Early treatment rescues bone lesions?. Molecular Genetics and Metabolism, 2015, 114, 195-202.	1.1	28
36	Activity of daily living for Morquio A syndrome. Molecular Genetics and Metabolism, 2016, 118, 111-122.	1.1	25

#	Article	IF	Citations
37	Tailoring the AAV2 capsid vector for bone-targeting. Pediatric Research, 2018, 84, 545-551.	2.3	25
38	Impairment of Body Growth in Mucopolysaccharidoses. , 2012, , 2091-2117.		15
39	Association between mucopolysaccharidosis Type VII and hydrops fetalis. Ultrasound in Obstetrics and Gynecology, 2020, 55, 416-417.	1.7	13
40	Enzyme replacement therapy on hypophosphatasia mouse model. Journal of Inherited Metabolic Disease, 2014, 37, 309-317.	3.6	12
41	Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry. Nihon Masu Sukurì„ningu Gakkaishi, 2014, 24, 19-37.	1.0	12
42	Enzyme Replacement Therapy with Elosulfase alfa for Mucopolysaccharidosis IVA (Morquio A) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	0.8	8
43	Sacral dimple: incidental findings from newborn evaluation (Discussion and Diagnosis). Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 910-912.	1.5	7
44	Biodegradable polyethylene glycol hydrogels for sustained release and enhanced stability of rhGALNS enzyme. Drug Delivery and Translational Research, 2020, 10, 1341-1352.	5.8	7
45	Abnormally increased carotid intima media-thickness and elasticity in patients with Morquio A disease. Orphanet Journal of Rare Diseases, 2020, 15, 73.	2.7	5
46	Umbilical mesenchymal stem cell-derived extracellular vesicles as enzyme delivery vehicle to treat Morquio A fibroblasts. Stem Cell Research and Therapy, 2021, 12, 276.	5.5	5
47	Causal Therapies in Mucopolysaccharidoses: Enzyme Replacement Therapy. Journal of Child Science, 2018, 08, e156-e162.	0.2	3
48	Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome. Journal of Clinical Investigation, 2020, 130, 1288-1300.	8.2	2
49	Therapies for the bone in mucopolysaccharidoses. Molecular Genetics and Metabolism, 2015, 114, S116.	1.1	1
50	50 Years Ago in T J P. Journal of Pediatrics, 2019, 215, 40.	1.8	1
51	Mucopolysaccharidosis IV (Morquio Syndrome). , 2007, , 433-445.		1
52	Mucopolysaccharidosis Type IVA: Extracellular Matrix Biomarkers in Cardiovascular Disease. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	1
53	Age-dependent gene expression profile analysis in Morquio syndrome type A mouse cartilage tissue. Molecular Genetics and Metabolism, 2015, 114, S49.	1.1	0
54	Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis type II. Molecular Genetics and Metabolism, 2017, 120, S77.	1.1	0

#	Article	IF	Citations
55	Injectable microgels development for sustained GALNS enzyme replacement therapy for Morquio syndrome type A. Molecular Genetics and Metabolism, 2017, 120, S70.	1.1	0
56	Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry. Molecular Genetics and Metabolism, 2017, 120, S78.	1.1	0
57	Carotid intima-media thickness and arterial stiffness are altered in patients with mucopolysaccharidosis type IVA. Molecular Genetics and Metabolism, 2017, 120, S136.	1.1	0
58	Advances in Mucopolysaccharidoses. Journal of Child Science, 2018, 08, e113-e115.	0.2	0
59	Growth patterns in subjects with mucopolysaccharidosis type VII. Molecular Genetics and Metabolism, 2021, 132, S72.	1.1	0